Understanding why guideline-concordant endometrial cancer treatment varies in high-risk groups
Official title: Understanding multilevel drivers of gaps in guideline-concordant endometrial cancer treatment in high-risk populations
Funded at Wake Forest University Health Sciences · NIH-11514616 · Data updated 2026-11-12
This project looks at why some patients with endometrial cancer don’t receive care that follows national guidelines, aiming to find ways to ensure more patients get the best-supported treatments.
Quick facts
| Grant type | R37 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Wake Forest University Health Sciences NIH-funded |
| Lab location | 1 site (Winston-Salem, United States) |
| Project start | July 1, 2022 |
| Project end | June 30, 2027 |
| Funding year | 2026 |
| Award (this year) | $488,515 |
| NIH project number | 7R37CA266204-05 |
| Project ID | NIH-11514616 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with endometrial cancer, especially from high-risk or underserved populations, whose care could be affected by guideline-concordant treatment decisions.
✕Less likely to help
Patients whose treatment decisions are already fully aligned with guidelines or who are not candidates for guideline-concordant interventions may see limited direct benefit.
What this research studies
Endometrial cancer outcomes vary across patient groups, and following guideline-concordant care is linked to better survival. The study will explore multilevel factors—patient, provider, and system-level—to understand why gaps exist in delivering guideline-based surgical staging and adjuvant therapy. By combining data and stakeholder perspectives, researchers hope to identify actionable barriers and inform interventions that improve care delivery without compromising quality of life. This work builds on prior findings that guideline-concordant treatment improves outcomes and seeks to translate those insights into real-world practice changes.
Why it matters
Potential benefit: If successful, the project could lead to strategies that reduce disparities and improve survival for diverse endometrial cancer patients.
How similar studies have gone: Previous work shows guideline-concordant treatment improves survival, supporting the potential impact of this approach.
Where this research is happening
-
Wake Forest University Health Sciences
Winston-Salem, United States Active
Researchers
- Principal investigator: Felix, Ashley S. — Wake Forest University Health Sciences
- Study coordinator: Felix, Ashley S.
Related research
Other NIH-funded projects on the same topics.
-
Prognostic tools to guide adjuvant therapy for Black women after hysterectomy for endometrial cancer
A new project aims to create and validate easy-to-use tools that help doctors tailor post-surgery treatment for Black women with endometrial cancer.
-
Targeting hormone resistance to prevent endometrial cancer
Aims to boost progesterone’s cancer-preventing effect in the lining of the uterus to stop cancer from developing in people at risk, especially those who are obese or young.
-
Inhibiting AXL to Improve Treatment Response in Endometrial Cancer
A cancer treatment study is testing whether blocking AXL with batiraxcept together with standard chemotherapy can help people with certain aggressive uterine cancers respond better.
-
Targeting HSPA Proteins to Help Women with Advanced or Recurrent Endometrial Cancer
Aims to test a drug called SHetA2 that may slow or stop growth of advanced endometrial cancer by targeting cancer-friendlier proteins, with a focus on reducing treatment toxicity.
-
Endometrial Cancer SPORE: New strategies to prevent and treat endometrial cancer
A multi-institution program is testing new ways to prevent and treat endometrial cancer in people, with three linked projects and multiple cores to support translational research.
-
Obesity-related metabolic changes and disparities in endometrial cancer
This project looks at why endometrial cancer is worse for Black women and whether obesity-related metabolic changes drive the disease, with aims to find ways to prevent or slow progression.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.